This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Biotinylated Human 2B4 / CD244 / SLAMF4 Protein, Avitag™,His Tag (recommended for biopanning)
catalog :
2B4-H82E9
quantity :
200 ug, 25 ug
price :
1380 USD, 350 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
2B4-H82E9
product name :
Biotinylated Human 2B4 / CD244 / SLAMF4 Protein, Avitag™,His Tag (recommended for biopanning)
quantity :
200 ug, 25 ug
price :
1380 USD, 350 USD
quantity & price :
$350/25ug,$1380/200ug
target :
2B4
host species :
Human
By Tag :
His Tag & Avi Tag
Research :
For Research Use Only
Source :
Biotinylated Human 2B4, Avitag,His Tag (recommended for biopanning) (2B4-H82E9) is expressed from human 293 cells (HEK293). It contains AA Cys 22 - Arg 221 (Accession # Q9BZW8-2).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Biotinylated Human 2B4, Avitag,His Tag (recommended for biopanning) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Natural killer cell receptor 2B4 is also known as NK cell type I receptor protein 2B4 (NKR2B4 or h2B4), SLAM family member 4 (SLAMF4), Signaling lymphocytic activation molecule 4, CD antigen CD244. NKR2B4 / CD244 contains two Ig-like (immunoglobulin-like) domains. CD244 is expressed in spleen, PBL, followed by lung, liver, testis and small intestine. CD244 interacts with CD48. Following phosphorylation, CD244 is able to recruit PTPN11/SHP-2 and SH2D1A/SAP. SLAMF4 modulate other receptor-ligand interactions to enhance leukocyte activation. CD244/2B4 is the only heterophilic receptor of SLAM family.
References :
(1) Nakajima H., et al., 1999, Eur. J. Immunol., 29:1676-1683.
(2) Kubin M.Z., et al., 1999, Eur. J. Immunol., 29:3466-3477.
(3) Boles K.S., et al., 1999, Tissue Antigens, 54:27-34.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments